| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
47,262,000 |
| Market
Cap: |
12.90(B) |
| Last
Volume: |
408,164 |
Avg
Vol: |
421,328 |
| 52
Week Range: |
$205.19 - $276.5 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile United Therapeutics is a biotechnology company. Through its subsidiary, Lung Biotechnology PBC, Co. is focused on addressing the acute national shortage of transplantable lungs and other organs with a variety of technologies that either delay the need for such organs or expand the supply. Co. markets and sells the following commercial therapies to treat pulmonary arterial hypertension: Remodulin® (treprostinil) Injection; Tyvaso® (treprostinil) Inhalation Solution; Orenitram® (treprostinil) Extended-Release Tablets; and Adcirca® (tadalafil) Tablets. In the U.S., Co. also markets and sells an oncology product, Unituxin® (dinutuximab) Injection, for the treatment of high-risk neuroblastoma.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
577,395 |
619,080 |
681,963 |
1,862,458 |
| Total Sell Value |
$140,716,560 |
$150,163,103 |
$164,291,315 |
$457,286,236 |
| Total People Sold |
8 |
8 |
8 |
11 |
| Total Sell Transactions |
69 |
79 |
91 |
266 |
| End Date |
2024-02-25 |
2023-11-24 |
2023-05-26 |
2022-05-26 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Benkowitz Michael |
President and COO |
• • – |
2021-10-26 |
4 |
OE |
$53.83 |
$215,320 |
D/D |
4,000 |
6,235 |
|
- |
|
| Benkowitz Michael |
President and COO |
• • – |
2021-10-21 |
4 |
D |
$190.66 |
$762,640 |
D/D |
(4,000) |
2,235 |
|
- |
|
| Benkowitz Michael |
President and COO |
• • – |
2021-10-21 |
4 |
OE |
$53.83 |
$215,320 |
D/D |
4,000 |
6,235 |
|
- |
|
| Mahon Paul A |
EVP & General Counsel |
• • – |
2021-10-21 |
4 |
AS |
$189.79 |
$1,141,082 |
D/D |
(6,000) |
36,369 |
|
-8% |
|
| Mahon Paul A |
EVP & General Counsel |
• • – |
2021-10-21 |
4 |
OE |
$111.00 |
$666,000 |
D/D |
6,000 |
42,369 |
|
- |
|
| Benkowitz Michael |
President and COO |
• • – |
2021-10-07 |
4 |
D |
$195.94 |
$783,760 |
D/D |
(4,000) |
2,235 |
|
- |
|
| Benkowitz Michael |
President and COO |
• • – |
2021-10-07 |
4 |
OE |
$53.83 |
$215,320 |
D/D |
4,000 |
6,235 |
|
- |
|
| Mahon Paul A |
EVP & General Counsel |
• • – |
2021-10-07 |
4 |
AS |
$190.07 |
$1,143,144 |
D/D |
(6,000) |
36,369 |
|
2% |
|
| Mahon Paul A |
EVP & General Counsel |
• • – |
2021-10-07 |
4 |
OE |
$111.00 |
$666,000 |
D/D |
6,000 |
42,369 |
|
- |
|
| Rothblatt Martine A |
Chairman & CEO |
• • – |
2021-09-28 |
4 |
GD |
$0.00 |
$0 |
I/I |
2,050 |
656,529 |
|
- |
|
| Benkowitz Michael |
President and COO |
• • – |
2021-09-23 |
4 |
D |
$200.47 |
$801,880 |
D/D |
(4,000) |
2,235 |
|
- |
|
| Benkowitz Michael |
President and COO |
• • – |
2021-09-23 |
4 |
OE |
$53.83 |
$215,320 |
D/D |
4,000 |
6,235 |
|
- |
|
| Benkowitz Michael |
President and COO |
• • – |
2021-09-21 |
4 |
D |
$198.83 |
$795,320 |
D/D |
(4,000) |
2,235 |
|
- |
|
| Benkowitz Michael |
President and COO |
• • – |
2021-09-21 |
4 |
OE |
$53.83 |
$215,320 |
D/D |
4,000 |
6,235 |
|
- |
|
| Rothblatt Martine A |
Chairman & CEO |
• • – |
2021-09-17 |
4 |
GD |
$0.00 |
$0 |
D/D |
10 |
130 |
|
- |
|
| Benkowitz Michael |
President and COO |
• • – |
2021-09-16 |
4 |
D |
$205.14 |
$820,560 |
D/D |
(4,000) |
2,235 |
|
- |
|
| Benkowitz Michael |
President and COO |
• • – |
2021-09-16 |
4 |
OE |
$53.83 |
$215,320 |
D/D |
4,000 |
6,235 |
|
- |
|
| Mahon Paul A |
EVP & General Counsel |
• • – |
2021-09-16 |
4 |
AS |
$203.36 |
$1,224,467 |
D/D |
(6,000) |
36,369 |
|
-5% |
|
| Mahon Paul A |
EVP & General Counsel |
• • – |
2021-09-16 |
4 |
OE |
$111.00 |
$666,000 |
D/D |
6,000 |
42,369 |
|
- |
|
| Benkowitz Michael |
President and COO |
• • – |
2021-09-14 |
4 |
D |
$208.47 |
$833,880 |
D/D |
(4,000) |
2,235 |
|
- |
|
| Benkowitz Michael |
President and COO |
• • – |
2021-09-14 |
4 |
OE |
$53.83 |
$215,320 |
D/D |
4,000 |
6,235 |
|
- |
|
| Rothblatt Martine A |
Chairman & CEO |
• • – |
2021-09-10 |
4 |
GD |
$0.00 |
$0 |
I/I |
3,787 |
658,579 |
|
- |
|
| Benkowitz Michael |
President and COO |
• • – |
2021-09-09 |
4 |
D |
$210.89 |
$843,560 |
D/D |
(4,000) |
2,235 |
|
- |
|
| Benkowitz Michael |
President and COO |
• • – |
2021-09-09 |
4 |
OE |
$53.83 |
$215,320 |
D/D |
4,000 |
6,235 |
|
- |
|
| Benkowitz Michael |
President and COO |
• • – |
2021-09-07 |
4 |
D |
$207.98 |
$831,920 |
D/D |
(4,000) |
2,235 |
|
- |
|
5052 Records found
|
|
Page 30 of 203 |
|
|
3.62 (1.31%) 
